Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On May 5, 2022, we announced that Jim Hollingshead resigned as our president -
sleep and respiratory care business, effective as of May 5, 2022, to pursue an
opportunity with a new employer. In connection with his resignation, Robert
("Rob") Douglas, our president and chief operating officer, has been appointed
to serve as our interim president - sleep and respiratory care business. We
intend to commence a search for a permanent president - sleep and respiratory
care business. A copy of the press release is furnished as Exhibit 99.1 to this
current report on Form 8-K.
Mr. Douglas was appointed ResMed Inc.'s president in March 2013 and chief
operating officer in September 2011; together with ResMed's chief executive
officer, Michael ("Mick") Farrell, he holds full operational responsibility for
ResMed and its subsidiaries.
There are no family relationships between Mr. Douglas and any director or
executive officer of ResMed that are required to be disclosed under Item 401(d)
of Regulation S-K, and there are no transactions between ResMed and Mr. Douglas
that would require disclosure under Item 404(a) of Regulation S-K. The
information concerning Mr. Douglas required under Item 401 of Regulation S-K is
contained in ResMed's proxy statement dated October 6, 2021 and is incorporated
here by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press release issued by ResMed Inc. on May 5, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL, document)
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses